In the era of digital health transformation, generative AI (GenAI) has emerged as a breakthrough technology in pharmacovigilance, the science dedicated to ensuring drug safety.
Pharma companies are moving their Generative AI (GenAI) investments from pilot to production through exploration, experimentation, industrialisation/scaling, adoption, and monetisation.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
